- Aripiprazole initiation was not associated with psychiatric treatment failure including psychiatric hospitalisation, self-harm or suicide vs another antipsychotic drug in patients previously exposed to antipsychotic medications.
Why this matters
- Some studies have reported a higher incidence of potential psychiatric worsening in first-time users of aripiprazole who have previously received antipsychotic treatment.
- Patients should, however, still be monitored when they switch to or add aripiprazole until current findings are confirmed in large studies.
- Study of 1643 patients switching or adding aripiprazole (either as a switch from or add-on to a previous antipsychotic medication) and propensity-matched patients switching to or adding another antipsychotic medication during 2005-2015.
- Funding: Canadian Institutes of Health Research and the Canadian Foundation for Innovation.
- Follow-up duration, 2692 person-years.
- 391 incident serious psychiatric treatment failures were observed (incidence rate of 14.52 per 100 person-years).
- Initiation of aripiprazole vs another antipsychotic medication was not associated with an increased rate of:
- psychiatric treatment failure (aHR, 0.87; 95% CI, 0.71-1.06);
- psychiatric hospitalisation (aHR, 0.85; 95% CI, 0.69-1.06) and
- self-harm or suicide (aHR, 0.96; 95% CI, 0.68-1.36).
- Psychiatric treatment failure was similar with aripiprazole vs another antipsychotic medication in:
- patients who recently received antipsychotic medication (aHR, 0.87; 95% CI, 0.67-1.15) and
- patients with schizophrenia (aHR, 0.82; 95% CI, 0.62-1.08).
- Observational design.